Perrigo's Papa: Bridge Over Valeant's Troubled Waters Or Shark Bait?
Executive Summary
Papa's 35 years of industry experience makes him "the ideal leader for Valeant at this time," since he remained in good stead with shareholders after getting other companies through tough times," Valeant says.
You may also be interested in...
Valeant Launches Lumify OTC Eye Drops With Vision Of Better Days As Bausch
Lumify eye drops, the first OTC brimonidine tartrate ophthalmic solution 0.025% in the US, will reach stores in late May. Corporate name change, says CEO Joseph Papa, shows Valeant is "beginning to turn the page away from legacy issues that have been headwinds over the past few years."
Valeant Launches Lumify OTC Eye Drops With Vision Of Better Days As Bausch
Lumify eye drops, the first OTC brimonidine tartrate ophthalmic solution 0.025% in the US, will reach stores in late May. Corporate name change, says CEO Joseph Papa, shows Valeant is "beginning to turn the page away from legacy issues that have been headwinds over the past few years."
Bausch Health Rises From Valeant's Simmering Ashes
Valeant will change its name to Bausch Health beginning in July and get a new ticker symbol, BHC, as the new management team looks to leave the company's checkered past behind.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: